You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
兄弟科技(002562.SZ):全資子公司取得藥品生產許可證
格隆匯 09-16 16:03

格隆匯9月16日丨兄弟科技(002562.SZ)公佈,公司全資子公司浙江兄弟藥業有限公司(以下簡稱兄弟藥業)於近日取得浙江省藥品監督管理局頒發的《藥品生產許可證》

生產地址和生產範圍:委託生產企業:華益藥業科技(安徽)有限公司,合肥市包河區工業區上海路11富馬酸比索洛爾片***

注:上述藥品生產許可證用於國內藥品註冊申請受理,在獲得富馬酸比索洛爾片藥品註冊證書後方可進行生產銷售

此次獲得《藥品生產許可證》,為兄弟藥業產品獲得上市許可、進行商業化生產與銷售提供了資質保障。在藥品上市許可持有人制度的全面實施下,公司將着力培育醫藥研發產業,不斷完善對藥品的全生命週期質量管理。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account